David Younger

David Younger

Chief Executive Officer & Co-Founder at A-Alpha Bio
Seattle, Washington, United States

David Younger is the Co-Founder and CEO of A-Alpha Bio, a Seattle-based biotechnology company applying synthetic biology and machine learning to engineer and predict protein-protein interactions. He is a co-inventor of the AlphaSeq platform, which enables quantitative measurements used in therapeutic antibody and molecular glue discovery. He previously worked as a postdoctoral researcher at the University of Washington.

IA40 Spotlight: A-Alpha Bio's David Younger on machine learning in biotech, building cross-functional teams

This week on Founded & Funded, Partner Chris Picardo is talking with A-Alpha Bio Co-founder and CEO David Younger for our first Intelligent Application 40 Spotlight episode of 2023. We announced the 2022 IA40 winners in October, and A-Alpha was the first biotech company to make the list, which was no surprise to us. As one of our portfolio companies, we know the work David and his team are doing at the intersections of biological and data/computer sciences will change the world — but having a group of judges agree with us makes us all the more certain. Protein interactions…

Organizations

See all 4
  • A-Alpha Bio logo
    A-Alpha Bio Executive Officer, Director 2019–present, Chief Executive Officer & Co-Founder 2017–present · current
  • University of Washington logo
    University of Washington Postdoctoral Researcher 2017–2018, Bioengineering Graduate Student 2012–2017 · past
  • Luminex Corporation Engineering Intern 2011 · past

Education

  • University of Washington Doctor of Philosophy (PhD), Bioengineering · 2012–2017
  • Rice University Bachelor of Science; Bachelor of Arts, Bioengineering, Economics · 2007–2012
  • The London School of Economics and Political Science (LSE) Economics · 2009–2010

Online